Sanofi Reaches an Agreement with Aqemia for $140 Million in Generative AI

Sanofi is committed to digitalization. The French pharmaceutical company has reached an agreement with the  medical start-up  Aqemia valued at $140 million (€129.5 million) to advance in  artificial intelligence (AI) applied to health.

Specifically, Sanofi will develop and research new therapeutic micromolecules through the use of generative AI and deep physics algorithms, as announced by the French pharmaceutical company in a statement.

Unlike other AI-based platform technologies that require chemical experimental data to train before beginning the design phase,  Aqemia will generate the data by performing calculations in-house.

Read more about the partnership between Sanofi and Aqemia, and find the most important business news of the day with our companion app Born2Invest

Sanofi closed 2022 with a profit of €6.83 billion, 8.8% more than in 2021

“This new partnership with Aqemia is part of a story that began with our French teams three years ago,” highlighted the vice president of Sanofi’s French research and development (R&D), Jacques Volckmann. The manager, precisely, has echoed how during that period interest was shown in the methods applied by Aqemia.

For his part, the CEO and co-founder of Aqemia, Maximilien Levesque, has been enthusiastic about the closed agreement. “This new step consists of expanding our experiences to multiple projects and helping Sanofi discover new chemical compounds on a large scale with our unique technology, even in difficult projects with limited chemical data up front and complex problems such as selectivity,” he explained. .

Paris-based Aqemia will receive upfront and milestone payments under the deal that will be used to deepen R&D. In addition, it plans to double its workforce to  one hundred workers  within a year.

Sanofi closed 2022 with a profit of €6.83 billion, which translates into an increase of 8.8% compared to 2021, according to the latest annual financial results published by the group.

Sanofi’s revenue last year amounted to €42.99 billion, compared to €37.76 billion recorded in 2021, so the year-on-year increase is 13.9%. By business area,  specialty care  had a turnover of €16.45 billion, 29.1% more than in 2021. General medicines reported sales of €14.23 billion in 2022, which translates into an increase of 0.1%. The pharmaceutical area earned €30.7 billion in 2022, 13.8% higher than in 2021. The vaccines segment earned €7.23 billion, 14.3% more, while  consumer healthcare  had a turnover of €5.8 billion, 13.7% more.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.